3 Undervalued Biotechnology & Medical Research Stocks for Wednesday, September 25
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Wednesday, September 25 based on AAII’s Stock Grades.Aneeqa Nadeem
Stock Evaluator: ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. NDRA
$6.05
0.37
6.51%
September 4, 2026 4:00:00 PM
EST
Volume: 20,582
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Commentary & Analysis
Is ENDRA Life Sciences Inc Stock (NDRA) a Good Investment?
Learn more about ENDRA Life Sciences Inc’s (NDRA) stock grades for Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Cynthia McLaughlin
Financial Summary
| Share Statistics | NDRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.1 | $423.0 | 6% |
|
| Shares Out (Mil) | 2.5 | 41.5 | 9% |
|
| Institutional Ownership | 68.4% | 83.6% | 42% |
|
| Float (Mil) | 1.4 | 35.5 | 4% |
|
| Beta | -0.07 | 0.88 | 5% |
|
| Avg Daily Volume (000s) | 65 | 346 | 32% |
|
| Price Change (52-week) |
42.0% | 65.4% | 77% |
|
| Growth | NDRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | 9.8% | (5.8%) | 55% |
|
| EPS (5yr) | na | 10.4% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.840) | ($3.540) | ($3.040) | |
| Month Ago EPS | ($0.840) | ($3.540) | ($3.040) | |
| # Rev Up | 1 | 1 | na | |
| # Rev Down | 0 | 0 | na | |
| Three Months Ago EPS | ($0.840) | ($3.540) | ($3.040) | |
| Year/Year Chg | (1,500%) | (60.4%) | na | |
| Financials | NDRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $119 | na |
|
| Net Income (TTM) (Mil) | ($6) | ($9) | 32% |
|
| EPS (TTM) | ($5.382) | ($0.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($3) | 25% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $1 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $23 | 13% |
|
| Enterprise Value (Q1) (Mil) | $5 | $376 | 6% |
|
| Valuation | NDRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.44 | 2.85 | 36% |
|
| P/E | na | 27.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | NDRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 58.5% | na |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (110.1%) | (13.3%) | 5% |
|
| ROE | (152.0%) | (13.3%) | 6% |
|
| Liabilities to Assets | 20.6% | 46.0% | 14% |
|
| F-Score | 3 | 4 | 18% |
|
ENDRA Life Sciences Inc. did not pass any screens on 9/4/2026.
